Zegerid launched in P Rico and Virgin Is
US drugmaker Santarus says that UK drug major GlaxoSmithKline has launched Zegerid (omeprazole/sodium bicarbonate) capsules and Zegerid powder for oral suspension in Puerto Rico and the US Virgin Islands.
The products were developed by Santarus and are the first and only immediate-release oral proton pump inhibitors commercialized in the USA. According to IMS Health, retail sales of prescription PPI products in Puerto Rico and the US Virgin Islands were approximately $124.0 million for the 12 months ended September 30, 2007, and grew at 24% compared with the prior 12 month period.
The move is a part of a distribution deal that San Diego-based Santarus signed with the UK firm (Marketletter December 10, 2007). GSK has exclusive rights to commercialize some of the former's prescription and over-the-counter immediate-release omeprazole products in Africa, Asia, the Middle East and both Central and South America. The deal includes 114 countries in the pharmaceutical major's international region.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze